Research programme: cancer therapeutics - Cancer Therapeutics CRCAlternative Names: MOZ inhibitor - Cancer Therapeutics CRC
Latest Information Update: 13 Jan 2017
At a glance
- Originator Cancer Therapeutics CRC
- Class Antineoplastics
- Mechanism of Action Histone acetyltransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Acute myeloid leukaemia
Most Recent Events
- 13 Jan 2017 Early research in Acute myeloid leukaemia in Australia before January 2017 (Cancer Therapeutics CRC pipeline, January 2017)